Core Viewpoint - Annoroad has submitted an application for listing on the Hong Kong Stock Exchange, with joint sponsors being CCB International and Guotai Junan International [1] Company Overview - The company specializes in IVD medical devices based on molecular diagnostics and multi-omics research services, particularly excelling in NGS-based prenatal testing IVD products [1] - Annoroad's clinical sequencing solutions include IVD testing kits, gene sequencers, and bioinformatics analysis software, along with technical support and laboratory design services [1] Market Position - In the NIPT market in China, Annoroad ranks second by sample testing volume with a market share of 15.5%, and third by revenue with a market share of 14.6% as of 2024 [1] - The company's research sequencing solutions serve multi-omics research in agriculture, forestry, animal husbandry, and fisheries [1] Production Facilities - As of September 23, 2025, the company operates three production facilities in China, primarily manufacturing testing kits and sequencers [1]
安诺优达递表港交所 联席保荐人为建银国际和国泰君安国际